LAZARD ASSET MANAGEMENT LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 173 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2019. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
LAZARD ASSET MANAGEMENT LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$123
+68.5%
3,490
+119.5%
0.00%
Q2 2023$73
-36.5%
1,590
-45.4%
0.00%
Q1 2023$115
-2.5%
2,910
+12.9%
0.00%
Q4 2022$118
-99.9%
2,578
+12.1%
0.00%
Q3 2022$95,000
+75.9%
2,299
+146.4%
0.00%
Q2 2022$54,000
-15.6%
933
+4.1%
0.00%
Q1 2022$64,000
+18.5%
896
+36.6%
0.00%
Q4 2021$54,000
+12.5%
656
+21.7%
0.00%
Q3 2021$48,000
-66.9%
539
-65.0%
0.00%
Q2 2021$145,000
+72.6%
1,539
+107.1%
0.00%
Q1 2021$84,000
-17.6%
7430.0%0.00%
Q4 2020$102,000
+72.9%
743
+2.2%
0.00%
Q3 2020$59,000
-29.8%
727
-32.7%
0.00%
Q2 2020$84,000
+3.7%
1,081
-41.1%
0.00%
Q1 2020$81,000
+350.0%
1,835
+322.8%
0.00%
Q4 2019$18,000
+80.0%
434
+70.2%
0.00%
Q3 2019$10,000
-99.4%
255
-98.9%
0.00%
-100.0%
Q1 2017$1,641,000
-5.7%
24,225
-2.1%
0.00%
-25.0%
Q4 2016$1,740,000
-0.9%
24,7500.0%0.00%
+33.3%
Q3 2016$1,755,000
+45.0%
24,7500.0%0.00%0.0%
Q2 2016$1,210,000
-22.7%
24,7500.0%0.00%0.0%
Q1 2016$1,566,000
-45.4%
24,750
-3.3%
0.00%
-57.1%
Q4 2015$2,870,000
+7.8%
25,590
-7.5%
0.01%
+16.7%
Q3 2015$2,662,00027,6500.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2019
NameSharesValueWeighting ↓
First Light Asset Management, LLC 437,512$31,772,0002.80%
RTW INVESTMENTS, LP 1,373,284$99,728,0002.06%
Rock Springs Capital Management LP 1,028,109$74,661,0001.88%
Privium Fund Management B.V. 112,727$8,186,0001.81%
Avidity Partners Management LP 869,000$63,107,0001.31%
SUVRETTA CAPITAL MANAGEMENT, LLC 525,100$38,133,0001.16%
Boxer Capital, LLC 200,000$14,524,0000.75%
SECTOR GAMMA AS 46,221$3,357,0000.73%
FEDERATED HERMES, INC. 3,987,728$289,589,0000.65%
EMERALD ADVISERS, LLC 223,952$16,263,0000.62%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders